Factor B inhibition for paroxysmal nocturnal haemoglobinuria

Affiliations

Comment

Robert A Brodsky. Lancet Haematol. 2021 May.

. 2021 May;8(5):e309-e310.

doi: 10.1016/S2352-3026(21)00061-2. Epub 2021 Mar 23.

¹ Department of Medicine, Division of Hematology, John Hopkins University, Baltimore, MD, USA. Electronic address: brodsro@jhmi.edu.

No abstract available

Comment on

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM, Röth A, Soret J, Frieri C, de Fontbrune FS, Marano L, Alashkar F, Benajiba L, Marotta S, Rozenberg I, Milojevic J, End P, Nidamarthy PK, Junge G, Peffault de Latour R. Risitano AM, et al. Lancet Haematol. 2021 May;8(5):e344-e354. doi: 10.1016/S2352-3026(21)00028-4. Epub 2021 Mar 23. Lancet Haematol. 2021. PMID: 33765419 Clinical Trial.